Zurcher Kantonalbank Zurich Cantonalbank trimmed its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 77.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,767 shares of the company’s stock after selling 16,200 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Novo Nordisk A/S were worth $243,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also added to or reduced their stakes in the stock. Franklin Resources Inc. boosted its holdings in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares during the period. Capital International Investors increased its holdings in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners purchased a new position in Novo Nordisk A/S during the 3rd quarter worth $310,199,000. SG Americas Securities LLC raised its position in Novo Nordisk A/S by 2,101.5% during the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock valued at $132,242,000 after purchasing an additional 2,274,925 shares in the last quarter. Finally, Clear Street Group Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at $56,378,000. 11.54% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
NVO has been the subject of several research reports. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a report on Tuesday, March 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a report on Tuesday, March 3rd. Finally, Citigroup began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $65.56.
Novo Nordisk A/S Stock Up 1.1%
Novo Nordisk A/S stock opened at $44.87 on Wednesday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The firm has a market cap of $200.34 billion, a P/E ratio of 12.93, a P/E/G ratio of 10.54 and a beta of 0.77. The business has a fifty day moving average of $38.45 and a two-hundred day moving average of $47.11. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.17. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, analysts forecast that Novo Nordisk A/S will post 3.34 earnings per share for the current fiscal year.
Trending Headlines about Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Q1 results beat expectations — adjusted operating profit topped forecasts and the market reacted positively, with coverage noting a share-price jump after the print. Reuters: Novo Nordisk’s first-quarter profit beats forecasts Invezz: Novo Nordisk gains 7% on Q1 beat
- Positive Sentiment: Wegovy pill launch is exceeding expectations — total prescriptions topped ~2 million since launch and early pill sales smashed forecasts, driving the guidance raise. CNBC: Wegovy sales smash forecasts after pill launch as Novo Nordisk hikes guidance WSJ: Wegovy Maker Lifts Guidance; prescriptions data
- Positive Sentiment: Management is pushing to expand the U.S. weight?loss market and says ~80% of Wegovy users are new patients — a signal the addressable market is growing, not just share-shifting. YouTube: Novo Nordisk CEO: Aim to expand U.S. weight-loss market YouTube Short: Novo CEO: 80% of Wegovy weight-loss users new
- Positive Sentiment: Board-authorized share repurchase program is underway (part of a DKK 15bn programme), which supports per?share metrics and can stabilize stock in the face of margin volatility. GlobeNewswire: Novo Nordisk share repurchase programme
- Neutral Sentiment: Updated 2026 revenue guidance set at $42.4B–$46.2B (consensus ~$45.4B); the wide range leaves ambiguity around upside vs. expectations and the company’s EPS guidance was not clearly specified in the release.
- Negative Sentiment: Heightened competition and a potential GLP?1 price war (notably with Eli Lilly) could compress prices and margins; investors will be watching whether rising prescriptions can offset pricing pressure. Reuters: Wegovy pill boom faces price war test Seeking Alpha: Earnings seen as inflection point amid GLP?1 pricing reset
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Further Reading
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
